AIM ImmunoTech announced a $2.65 million financing through a registered direct offering and private placement priced at market under NYSE American rules. The company will issue over 2.5 million shares of common stock and unregistered shares with warrants, with proceeds aimed at manufacturing clinical drug supplies, supporting ongoing and planned Phase 3 clinical trials, and general working capital. The offering is expected to close around June 10, 2026, and is managed by Ladenburg Thalmann & Co. This funding supports AIM ImmunoTech's development of Ampligen®, a drug in trials for cancers, immune disorders, and viral diseases.
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
